EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
|Videos|August 10, 2022
Dr. Syan on her clinical experience with implantable SNM treatment for bladder/bowel dysfunction
Author(s)Urology Times staff
Advertisement
Raveen Syan, MD, discusses her clinical experience with sacral neuromodulation implantable neurostimulator treatment for patients with bladder and bowel dysfunction. Syan is an assistant professor of Clinical Urology at the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.
Advertisement
Related to this article
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
A recap of the FDA submissions and regulatory decisions in urology from August 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5